Skip to main content
main-content

08.01.2016 | Retinal Disorders | Ausgabe 9/2016

Graefe's Archive for Clinical and Experimental Ophthalmology 9/2016

Gas-mediated vitreomacular adhesion release with intravitral ranibizumab injections for exudative age-related macular degeneration

Zeitschrift:
Graefe's Archive for Clinical and Experimental Ophthalmology > Ausgabe 9/2016
Autoren:
Hae Min Kang, Sung Jun Lee, Chul Gu Kim, Eun Jee Chung, Hyoung Jun Koh

Abstract

Purpose

To evaluate the efficiency of gas-assisted vitreomacular adhesion (VMA) release combined with intravitreal ranibizumab injections for exudative age-related macular degeneration (AMD) patients.

Materials and methods

This prospective, interventional case series included a total of 23 eyes of 22 patients. The eyes were treated with intravitreal injection of 0.3 mL of perfluoropropane (C3F8) gas and concomitant intravitreal ranibizumab injection to stimulate VMA release. After three initial loading injections, additional intravitreal ranibizumab injections were performed pro re nata. Over a 12-month period, monthly examinations were performed for best-corrected visual acuity (BCVA, logMAR; logarithm of the minimum angle resolution), optical coherence tomography, and dilated fundus examinations.

Results

After gas injection, 22 eyes (95.7 %) showed complete VMA release at 1 week. Complete VMA was achieved in all eyes at 2 months after VMA release, without serious ocular adverse events except one patient who developed a retinal tear. Mean BCVA was 0.61 ± 0.37 logMAR (20/81 Snellen equivalents) at baseline and 0.46 ± 0.30 logMAR (20/57 Snellen equivalents) at 12 months (P = 0.135). Mean central macular thickness was 357.9 ± 128.6 μm at baseline and 245.6 ± 60.0 μm at 12 months (P = 0.188). Mean numbers of intravitreal ranibizumab injections were 4.8 ± 2.4 times during 12 months (4 to 8 injections).

Conclusion

Gas-assisted VMA release can be used as an efficient alternative for exudative AMD patients with obvious VMA.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 9/2016

Graefe's Archive for Clinical and Experimental Ophthalmology 9/2016 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

10.02.2021 | Katarakt | Leitthema | Ausgabe 3/2021

Therapie der postoperativen Endophthalmitis

Operieren oder nur injizieren?

08.02.2021 | Vaskulitiden | Übersichten | Ausgabe 3/2021 Open Access

Intraokulare Entzündungen bei Brolucizumab-Anwendung

Patientenmanagement – Diagnose – Therapie

28.01.2021 | themenschwerpunkt | Ausgabe 1/2021 Open Access

Fünfzig Jahre Schielbehandlung – Ein Erfahrungsbericht aus Klinik und Praxis

26.01.2021 | themenschwerpunkt | Ausgabe 1/2021

MISS (minimalinvasive Schielchirurgie) zur Strabismuskorrektur